# US 2011/0257213 A1 · Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257213 A1
- Document ID: US20110257213A1
- Status: Published application
- Kind: A1
- Application number: 13/151,946
- Filed: 2011-06-02
- Published: 2011-10-20
- Earliest claimed: 2008-12-05
- Assignees: Sanofi
- Inventors: Zhongli GAO; Daniel HALL; Ryan HARTUNG
- Web page: https://patentgrep.com/patent/US20110257213A1

## CPC

- C07D 471/10: Spiro-condensed systems
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). wherein R1, R2, R3, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefor are disclosed.

## Claims

### Claim 1

A compound of formula (I):
wherein
m is 1 or 2;
n is 1 or 2;
p is 1 or 2;
R1 is hydrogen, (C1-C4)alkyl, CF3, or (C1-C4)alkoxy-(C1-C4)alkyl;
R2 is hydrogen, halogen, (C1-C4)alkyl or CF3; and
R3 is hydrogen, (C1-C4)alkyl, (C1-C6)alkyloxycarbonyl, (C3-C7)cycloalkyl(C1-C6)alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted heterocycloalkyl(C1-C6)alkyl, substituted or unsubstituted 5- or 6-membered ring heteroaryl(C1-C6)alkyl, substituted or unsubstituted benzyl, (C1-C4)alkoxymethylcarbonyl, substituted or unsubstituted (C3-C7)cycloalkanecarbonyl, substituted or unsubstituted benzylcarbonyl, substituted or unsubstituted (C6-C10)arylcarbonyl, substituted or unsubstituted 5 or 6-membered ring heteroarylcarbonyl, substituted or unsubstituted heterocyclecarbonyl, substituted or unsubstituted benzenesulfonyl, wherein the substituents are selected from halogen, trifluoromethoxy, (C1-C4)alkoxy, (C1-C4)alkyl and CF3;
or a salt, enantiomer or diastereomer thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein
n, p, and m are 1;
R1 is methyl, ethyl, isopropyl, n-propyl or methoxymethyl;
R2 is hydrogen, fluorine, chlorine, methyl, ethyl or CF3; and
R3 is hydrogen, methoxyethylcarbonyl, tert-butyloxycarbonyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, tetrahydropyranyl, benzyl, furanylmethyl, cyclopentane-carbonyl, cyclohexanecarbonyl, trifluoromethoxybenzoyl, fluorobenzoyl, benzyl-carbonyl, naphthylcarbonyl, benzenesulfonyl, fluorobenzene sulfonyl or methoxybenzenesulfonyl;
or a salt, enantiomer or diastereomer thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein
n is 2 and m is 1; or
n is 1 and m is 2;
p is 1 or 2;
R1 is methyl or ethyl;
R2 is hydrogen, fluorine, chlorine, methyl, ethyl or CF3; and
R3 is hydrogen, isopropyl, tert-butyloxycarbonyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, tetrahydropyranyl, benzyl, furanylmethyl, tetrahydropyranylmethyl, cyclopentane carbonyl, cyclohexane carbonyl, tetrahydropyran carbonyl, benzoyl, trifluoromethoxybenzoyl, fluorobenzoyl, benzyl carbonyl, naphthyl carbonyl, pyridine carbonyl or furan carbonyl;
or a salt, enantiomer or diastereomer thereof.

### Claim 4 (depends on 1)

The compound of claim 1 selected from the group consisting of:
2-[2-methyl-4-((2R,3′S)-2-methyl-[1,3]bipyrrolidinyl-1′-yl)-phenyl]-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-[2-methyl-4-((2R,3′R)-2-methyl-[1,3]bipyrrolidinyl-1′-yl)-phenyl]-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-[2-methyl-4-((2S,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-[2-methyl-4-(2-methyl-[1,3]bipyrrolidinyl-1′-yl)-phenyl]-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-1-oxo-2,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester;
2-[4-((2S,3′S)-2-methyl-[1,3]bipyrrolidinyl-1′-yl)-phenyl]-1-oxo-2,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester;
4-{[2-fluoro-4-((2S,3′S)-2-methyl-[1,3]bipyrrolidinyl-1′-yl)-phenyl]-methyl-carbamoyl}-4-propyl-piperidine-1-carboxylic acid tert-butyl ester;
2-{4-[4-(2S-2-methyl-pyrrolidin-1-yl]-piperidin-1′-yl)-phenyl}-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-{4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-trifluoromethyl-phenyl}-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-{4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-fluoro-phenyl}-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-phenyl}-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-2-trifluoromethyl-phenyl}-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-2-fluoro-phenyl}-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester;
2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3]bipyrrolidinyl-t-yl)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-[2-methyl-4-(2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
8-benzenesulfonyl-2-{4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
8-(4-methoxy-benzenesulfonyl)-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2R,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2R,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2S,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-[2-methyl-4-((2R,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-l)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-[2-methyl-4-((2R,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-l)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-[2-methyl-4-((2S,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-l)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3]bipyrrolidinyl-1′-l)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2R,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2R,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2S,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-(2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
3-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
3-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
3-[2-fluoro-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
3-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-9-(pyridine-4-carbonyl)-2,9-diaza-spiro[5.5]undecan-1-one;
9-(furan-3-carbonyl)-2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
9-benzoyl-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
9-(4-fluoro-benzoyl-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
9-cyclohexanecarbonyl-2-[2-fluoro-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
2-[2-fluoro-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-9-(tetrahydro-pyran-4-carbonyl)-2,9-diaza-spiro[5.5]undecan-1-one;
9-isopropyl-2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
9-cyclohexylmethyl-2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
9-cyclopropylmethyl-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-9-(tetrahydro-pyran-4-yl)-2,9-diaza-spiro[5.5]undecan-1-one;
9-benzyl-2-[2-fluoro-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
2-[2-fluoro-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-9-furan-2-ylmethyl-2,9-diaza-spiro[5.5]undecan-1-one;
2-{4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
2-{4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-trifluoromethyl-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
2-{4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-fluoro-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-2-trifluoromethyl-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-2-fluoro-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
8-(4-fluoro-benzoyl)-2-{4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclohexanecarbonyl-2-{2-fluoro-4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
8-(4-fluoro-benzenesulfonyl)-2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-phenyl}-8-(tetrahydro-pyran-4-carbonyl)-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentanecarbonyl-2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-2-trifluoromethyl-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopropylmethyl-2-{2-fluoro-4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-{2-fluoro-4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclohexylmethyl-2-{4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-2-trifluoromethyl-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
2-{2-fluoro-4-[3-((2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-phenyl}-8-(tetrahydro-pyran-4-ylmethyl)-2,8-diaza-spiro[4.5]decan-1-one;
2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-8-phenylacetyl-2,8-diaza-spiro[4.5]decan-1-one;
8-(2-methoxy-acetyl)-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-8-(naphthalene-2-carbonyl)-2,8-diaza-spiro[4.5]decan-1-one;
8-benzoyl-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-(furan-3-carbonyl)-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-furan-2-ylmethyl-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopropylmethyl-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-8-(tetrahydro-pyran-4-ylmethyl)-2,8-diaza-spiro[4.5]decan-1-one; and
2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
or a salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1 selected from the group consisting of:
8-cyclopentylmethyl-2-[2-methyl-4-((2R,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-l)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-[2-methyl-4-((2R,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-l)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-[2-methyl-4-((2S,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-l)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3]bipyrrolidinyl-1′-l)-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2R,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2R,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-((2S,3′R)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
2-[2-methyl-4-(2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-8-(4-trifluoromethoxy-benzoyl)-2,8-diaza-spiro[4.5]decan-1-one;
3-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
3-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
3-[2-fluoro-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
9-isopropyl-2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
9-cyclohexylmethyl-2-[2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
9-cyclopropylmethyl-2-[4-((2S,3′S)-2-methyl-[1,3]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-9-(tetrahydro-pyran-4-yl)-2,9-diaza-spiro[5.5]undecan-1-one;
9-benzyl-2-[2-fluoro-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-phenyl]-2,9-diaza-spiro[5.5]undecan-1-one;
2-[2-fluoro-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-t-yl)-phenyl]-9-furan-2-ylmethyl-2,9-diaza-spiro[5.5]undecan-1-one;
8-cyclopropylmethyl-2-{2-fluoro-4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopentylmethyl-2-{2-fluoro-4-[4-(2S-2-methyl-pyrrolidin-1-yl)-piperidin-1-yl]-phenyl}-2,8-diaza-spiro[4.5]decan-1-one;
2-{2-fluoro-4-[34(2S,3′S)-2-methyl-piperidin-1-yl)-pyrrolidin-1-yl]-phenyl}-8-(tetrahydro-pyran-4-ylmethyl)-2,8-diaza-spiro[4.5]decan-1-one;
8-furan-2-ylmethyl-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one;
8-cyclopropylmethyl-2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-2,8-diaza-spiro[4.5]decan-1-one; and
2-[4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)-2-trifluoromethyl-phenyl]-8-(tetrahydro-pyran-4-ylmethyl)-2,8-diaza-spiro[4.5]decan-1-one;
or a salt thereof.

### Claim 6 (depends on 1)

The compound according or claim 1 which has the formula (II):
wherein R1, R2, R3, m and n are as defined in claim 1.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising one or more compound of claim 1 or a pharmaceutically acceptable salt, an enantiomer, or a diastereomer thereof in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 8 (depends on 2)

A pharmaceutical composition comprising one or more compound of claim 2 or a pharmaceutically acceptable salt, an enantiomer, or a diastereomer thereof in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 9 (depends on 3)

A pharmaceutical composition comprising one or more compound of claim 3 or a pharmaceutically acceptable salt, an enantiomer, or a diastereomer thereof in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 10 (depends on 4)

A pharmaceutical composition comprising one or more compound of claim 4 or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 11 (depends on 5)

A pharmaceutical composition comprising one or more compound of claim 5 or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 12 (depends on 1)

A method of treating a disease in a patient, said disease selected from the group consisting of a sleep disorder, dementia, Alzheimer's disease, multiple sclerosis, cognitive disorder, attention deficit hyperactivity disorder and depression, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the sleep disorder is selected from the group consisting of narcolepsy, circadian rhythm sleep disorder, obstructive sleep apnea, periodic limb movement and restless leg syndrome, excessive sleepiness and drowsiness due to medication side-effect.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the sleep disorder is narcolepsy.

### Claim 15 (depends on 1)

A method for treating a disease in a patient, said disease selected from the group consisting of cognitive impairment associated with schizophrenia (CIAS), an anxiety disorder, panic disorder and post-traumatic stress disorder, major depressive disorder, dementia of Alzheimer type (DAT), cognitive deficits related to neurological diseases chosen from Alzheimer, Parkinson or Huntington, age related cognitive impairment, mild cognitive impairment, vascular dementia, Lewis Body dementia, cognition associated with cognitive deficits, and obesity comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the disease is cognitive impairment associated with schizophrenia (CIAS).

### Claim 17 (depends on 15)

The method according to claim 15, wherein the disease is dementia of Alzheimer type (DAT).
